Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-01-09
2007-01-09
Coleman, Brenda (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C540S505000, C540S509000, C540S512000, C540S572000
Reexamination Certificate
active
09980680
ABSTRACT:
The present invention provides a compound of formula (I):wherein all variables are as defined herein, pharmaceutical formulations containing the same, processes for preparing the same and their use therapy.
REFERENCES:
patent: 4755508 (1988-07-01), Bock et al.
patent: 5324726 (1994-06-01), Bock et al.
patent: 5665718 (1997-09-01), Godel et al.
patent: 5698691 (1997-12-01), Yukimasa et al.
patent: 5834464 (1998-11-01), Bock et al.
patent: 2002/0055500 (2002-05-01), Wu et al.
patent: 40183 (1959-12-01), None
patent: FR 2 034 577 (1970-12-01), None
patent: FR 2 115 265 (1972-07-01), None
patent: FR 2 183 716 (1973-12-01), None
patent: FR 2 231 385 (1974-12-01), None
patent: CH 608 234 (1978-12-01), None
patent: 166356 (1986-01-01), None
patent: 167919 (1986-01-01), None
patent: 0 264 797 (1988-04-01), None
patent: 284256 (1988-09-01), None
patent: 434360 (1991-06-01), None
patent: 434364 (1991-06-01), None
patent: 0 508 798 (1992-10-01), None
patent: 523845 (1993-01-01), None
patent: 176 927 (1993-09-01), None
patent: 727215 (1996-08-01), None
patent: 881 235 (1998-12-01), None
patent: 2259013 (1993-03-01), None
patent: 7012813 (1970-08-01), None
patent: FR 2414043 (1979-08-01), None
patent: EP 0100 906 (1984-02-01), None
patent: EPO 122 889 (1984-10-01), None
patent: WO 91 05549 (1991-05-01), None
patent: WO 96 23790 (1995-08-01), None
patent: WO 96 20941 (1996-07-01), None
patent: WO 98 00405 (1998-01-01), None
patent: WO 98/38177 (1998-09-01), None
Ichihara, Masato et al., “Preparation of diazepine derivatives as specific inhibitors of human renin”,Database Chemabs Online!, Chemical Abstracts Service, (1995).
Goumri-Magnet S. et al., “Free and Supported Phosphorus Ylides as Strong Neutral Bronsted Bases”,Journal of Organic Chemistry, vol. 64, No. 10, (1999), pp. 3741-3744.
Avdagic, Amir et al., “Lipase-catalyzed acetylation of 3-substituted 2,3-dihydro-1H-1,4-bezodiazepin-2-ones. Effect of temperature and conformation on enantioselectivity and configuration”,Helv. Chim. Acta, vol. 81, No. 8, pp. 1567-1582, (1998).
Heaney, Frances et al., “Steric control of reactivity: formation of oximes, benzodiazepinone N-oxides and isoxazoloquinolinones”,Journal Chem. Soc., Perkin Trans. vol. 2, (3), (1998), pp. 547-559.
Bock, Mark G. et al., “Curtius rearrangement in the 5-phenyl-1,4-benzodiazepine series. Unprecendedted participation by an imine nitrogen”,Journal Heterocycl. Chem.,vol. 27, No. 3, (1990), pp. 631-636.
Manghisi, E. et al., Synthesis and central nervous effects of some 3-substituted 1,4-benzodiazepin-2-ones,Boll. Chim. Farm., vol. 113, No. 12, (1974), pp. 642-644.
Corbella, Attilio et al., “Stereochemistry of the enzymic 3-hydroxylation of 1,3-dihydro-22H-1,4-benzodiazepin-2-ones”,J. Chem. Soc., Chem. Commun., No. 19, (1973), pp. 721-722.
Walser, Armin et al., “Quinazolines and 1,4-benzodiazepines. LIX. Preparation of pyrrolo'2,1-c!-1,4-benzodiazepines”,J. Org. Chem.,vol. 38, No. 20, (1973), pp. 3502-3507.
Shimamoto, Kiro et al., “Pharmaceutical screening of new benzodiazepines in mice”,Takeda Kenkyusho Ho, vol. 29, No. 1, (1970) pp. 134-144.
Gilman, A.G., et al. “Goodman and Gilman's The Pharmacological Basis of Therapeutics.” Eighth Edition, Pergamon Press: New York, 1990; pp. 303-304, 346-358.
Hering, W., et al. “CNS Effects of the New Benzodiazepines RO 48-6791 and RO 48-8684 Compared to Midazolam in Young and Elderly Volunteers.” Anesthesiology 1996, 189, 85 (Suppl.).
Dingemanse, J. et al. “Pharmacokinetic-Pharmacodynamic Modelling of the EEF Effects of RO 48-6791, a New Short-Acting Benzodiazepine, in Young and Elderly Subjects.” Br. J. Anaesth. 1997, 79, pp. 567-574.
Khan, W.A., et al. “Synthesis of 3-Substituted 1,4-Benzodiazepine2-Ones.” Org. Prep. Proc. Int., 1978, 10, pp. 105-111.
Hester, J.B., et al. “8-Chloro-1-methyl-6-phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepines with Substituents at C-4” J. Med. Chem., 1980, 23, 643-647.
Bauer, T.M., et al. “Prolonged Sedation Due to Accumulation of Conjugated Metabolites of Midazolam.” Lancet 1995, 346, pp. 145-147.
Shafer, A., et al. “Complications of Sedation with Midazolam in the Intensive Care Unit and a Comparison wit Other Sedative Regimens.” Crit. Care Med., 1998, 26, 947-956.
Feldman Paul L
Jung David Kendall
Kaldor Istvan
Pacofsky Gregory J.
Stafford Jeffrey A.
CeNeS Limited
Coleman Brenda
Corless Peter F.
Edwards Angell Palmer & & Dodge LLP
LandOfFree
Short-acting benzodiazepines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Short-acting benzodiazepines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Short-acting benzodiazepines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3782799